CurrentCignaPolicy IP0293

Aranesp

Defines Cigna's coverage, prior authorization, dosing limits, and duration for Aranesp (darbepoetin alfa) for anemia indications (CKD on/off dialysis, chemotherapy-related, MDS, myelofibrosis) and lists noncovered uses and applicable J-codes.

Policy Summary

PayerCigna

PolicyAranesp

Policy CodePolicy IP0293

Change TypeAnnual revision (title, indications, dosing, criteria updates)

Effective DateSep 15, 2025

Next Review Date

Key ActionObtain prior authorization and document iron status and prescriber specialty; ensure billed doses meet policy dosing limits.

POLICY UPDATE CHANGES

Updated title from 'Darbepoetin Alfa' to 'Erythropoiesis-Stimulating Agents - Aranesp'; added indications and dosing, added 'Patient is Currently Receiving an Erythropoiesis-Stimulating Agent' criteria and added language 'According to the prescriber, myelosuppressive chemotherapy is considered non-curative.'

5Covered Indications (listed)

5Not Covered Uses (examples listed)

2J-codes specified

Coverage Summary

Coverage stance: covered with criteria for Aranesp (darbepoetin alfa). Scope: Cigna’s policy defines coverage, prior authorization, dosing limits, and approval durations for anemia indications including CKD (on dialysis and not on dialysis), chemotherapy-related anemia for non-myeloid malignancies receiving myelosuppressive chemotherapy with ≥ two additional months planned, and supportive uses such as myelodysplastic syndrome (MDS) and myelofibrosis per cited guidance and the policy criteria. Approval durations specified in the policy include: 3 years for anemia in CKD patients who are on dialysis, 1 year for anemia in CKD patients who are not on dialysis, and 6 months for anemia due to cancer chemotherapy. The policy lists conditions considered not medically necessary (examples): anemia in cancer patients not receiving myelosuppressive chemotherapy, anemia associated with AML/CML or other myeloid cancers, anemia associated with radiotherapy-only, use to enhance athletic performance, and anemia due to acute blood loss.

FDA-Approved Indications - Anemia in CKD who is on Dialysis

Approve for 3 years when ALL of the following are met:

ALL of the following

Indication: Anemia in a patient with chronic kidney disease who is on dialysis
General policy requirement
Prescribed by or in consultation with a physician who specializes in the condition being treated

FDA-Approved Indications - Anemia in CKD who is not on Dialysis

Approve for 1 year if the patient meets ONE of the following (A or B):

ANY of the following

A) Initial Therapy
- i. Hemoglobin entry criteria
  - a) Adult: Patient is ≥ 18 years of age with a hemoglobin < 10.0 g/dL< 10.0 g/dL
  - b) Pediatric: Patient is < 18 years of age with a hemoglobin ≤ 11.0 g/dL≤ 11.0 g/dL
- ii. Iron status
  - Patient is currently receiving iron therapy
  - Patient has adequate iron stores according to the prescriber
B) Patient is Currently Receiving an Erythropoiesis-Stimulating Agent
- i: Patient has a hemoglobin ≤ 12.0 g/dL≤ 12.0 g/dL
- ii. Iron status
  - Patient is currently receiving iron therapy
  - Patient has adequate iron stores according to the prescriber

Dosing for CKD (not on dialysis)

Approve ONE of the following dosing regimens (A or B):

ANY of the following

A) Adult dosing (≥ 18 years)
- i: Each dose is ≤ 0.45 mcg/kg≤ 0.45 mcg/kg
- ii: Each dose is given no more frequently than once every 4 weeksq4w maximum
B) Pediatric dosing (< 18 years)
- i: Each dose is ≤ 0.75 mcg/kg≤ 0.75 mcg/kg
- ii: Each dose is given no more frequently than once every 2 weeksq2w maximum

FDA-Approved Indications - Anemia in Cancer due to Chemotherapy

Approve for 6 months if the patient meets ONE of the following (A or B):

ANY of the following

A) Initial Therapy
- i: Patient has a hemoglobin < 10.0 g/dL< 10.0 g/dL
- ii. Chemotherapy status
  - a: Patient is currently receiving myelosuppressive chemotherapy
  - b: According to the prescriber, myelosuppressive chemotherapy is considered noncurative
- iii. Iron status
  - Patient is currently receiving iron therapy
  - Patient has adequate iron stores according to the prescriber
B) Patient is Currently Receiving an ESA
- i: Patient has a hemoglobin ≤ 12.0 g/dL≤ 12.0 g/dL
- ii: Patient is currently receiving myelosuppressive chemotherapy
- iii: According to the prescriber, myelosuppressive chemotherapy is considered noncurative
- iv. Iron status
  - Patient is currently receiving iron therapy

Dosing for Cancer Chemotherapy Indication

Approve ONE of the following dosing regimens (A or B):

ANY of the following

A) Adult dosing (≥ 18 years)
- i: Each dose is ≤ 500 mcg≤ 500 mcg
- ii: Each dose is given no more frequently than once every weekq1w maximum
B) Pediatric dosing (< 18 years)
- i: Each dose is ≤ 2.25 mcg/kg≤ 2.25 mcg/kg
- ii: Each dose is given no more frequently than once every weekq1w maximum

Other Uses with Supportive Evidence - Myelodysplastic Syndrome (MDS)

Approve for 1 year if the patient meets ONE of the following (A or B):

ANY of the following

A) Initial Therapy
- Patient is ≥ 18 years of age≥ 18 years
- ii. Hemoglobin/erythropoietin
  - a: Patient has a hemoglobin < 10.0 g/dL< 10.0 g/dL
  - b: Patient has a serum erythropoietin level ≤ 500 mU/mL≤ 500 mU/mL
- iii. Iron status
  - Patient is currently receiving iron therapy
  - Patient has adequate iron stores according to the prescriber
- The medication is prescribed by or in consultation with a hematologist or oncologist
B) Patient is Currently Receiving an ESA
- Patient is ≥ 18 years of age≥ 18 years
- Patient has a hemoglobin ≤ 12.0 g/dL≤ 12.0 g/dL
- iii. Iron status
  - Patient is currently receiving iron therapy
  - Patient has adequate iron stores according to the prescriber
- The medication is prescribed by or in consultation with a hematologist or oncologist

Other Uses with Supportive Evidence - Myelofibrosis

Approve if criteria met; duration and approval depend on initial vs continuing therapy:

ANY of the following

A) Initial Therapy
- i. Hemoglobin/erythropoietin
  - a: Patient has a hemoglobin < 10.0 g/dL< 10.0 g/dL
  - b: Patient has a serum erythropoietin level ≤ 500 mU/mL≤ 500 mU/mL
- ii. Iron status
  - Patient is currently receiving iron therapy
  - Patient has adequate iron stores according to the prescriber
- The medication is prescribed by or in consultation with a hematologist or oncologist
B) Patient is Currently Receiving an ESA
- Patient has a hemoglobin ≤ 12.0 g/dL≤ 12.0 g/dL
- ii. Iron status
  - Patient is currently receiving iron therapy
  - Patient has adequate iron stores according to the prescriber
- According to the prescriber, patient has responded to therapy defined as hemoglobin ≥ 10 g/dL or a hemoglobin increase of ≥ 2 g/dLHb ≥ 10 g/dL or increase ≥ 2 g/dL
- The medication is prescribed by or in consultation with a hematologist or oncologist

General Policy Requirements

Applies to approvals across indications:

ALL of the following

Prior authorization is required for benefit coverage of Aranesp in patients with conditions other than CKD who are on dialysis
Aranesp must be prescribed by or in consultation with a physician who specializes in the condition being treated
Extended approvals allowed if patient continues to meet criteria and dosing
Requests for doses outside established dosing will be considered case-by-case by a clinician (Medical Director or Pharmacist)

Conditions Not Covered (Not Medically Necessary)

Aranesp for any other use is considered not medically necessary, including but not limited to:

ANY of the following

Anemia associated with cancer in a patient not receiving myelosuppressive cancer chemotherapy
Anemia associated with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), or other myeloid cancers
Anemia associated with radiotherapy in cancer when patients are given only radiation therapy
To enhance athletic performance
Anemia due to acute blood loss

Provider Actions & Billing

Prior Authorization

Prior authorization required

Prior authorization is required for Aranesp benefit coverage for conditions other than CKD patients on dialysis. Approvals are provided for specified durations (for example: 3 years for CKD on dialysis; 1 year for CKD not on dialysis; 6 months for chemotherapy-related anemia).

J0881
J0882

Documentation Required

Prescriber specialty requirement

Aranesp must be prescribed by or in consultation with a physician who specializes in the condition being treated. For supportive uses such as myelodysplastic syndrome (MDS) and myelofibrosis, the policy requires prescription by or in consultation with a hematologist or oncologist.

Documentation Required

Iron status documentation

Document the patient’s iron status before approval. The policy requires documentation that the patient is currently receiving iron therapy or has adequate iron stores according to the prescriber for initiation or continuation across indications (CKD, chemotherapy-related anemia, MDS, myelofibrosis).

Billing Rule

Dose limit billing

Ensure billed doses meet the policy’s dosing limits. Requests for doses outside the established dosing will be reviewed case‑by‑case; claims not meeting dosing limits may not be approved.

J0881
J0882

Denial Risk

Not covered uses

Claims for listed noncovered indications will be denied as not medically necessary. Examples include anemia in cancer patients not receiving myelosuppressive chemotherapy, anemia associated with AML or CML or other myeloid cancers, anemia with radiotherapy-only, use to enhance athletic performance, and anemia due to acute blood loss.

Clinical Evidence & References

Evidence cited in the policy includes the Aranesp prescribing information (Amgen; May 2024) and clinical practice guidelines: KDIGO Clinical Practice Guideline for Anemia in CKD (2025) and NCCN guidelines (2024–2025 versions). The policy references guideline recommendations to address correctable causes of anemia (including iron deficiency) before initiating ESA therapy and to use ESAs as first-line therapy versus HIF-PHIs after correctable causes are managed. The policy and prescribing information emphasize that iron status should be evaluated before and during treatment and that dosing is titrated based on hemoglobin response, using the lowest effective dose and following recommended dose adjustments (increases, reductions, interruptions, or conversions) per the prescribing information.

Background

Background: Aranesp (darbepoetin alfa) is an erythropoiesis-stimulating agent (ESA) indicated for anemia due to chronic kidney disease (both patients on dialysis and not on dialysis), for anemia from myelosuppressive chemotherapy in non-myeloid malignancies with at least two additional months of planned chemotherapy, and for supportive uses including MDS and myelofibrosis as noted in cited guidelines. Iron status monitoring is required — the policy states that iron status should be evaluated before and during ESA therapy and that iron replacement may be necessary to optimize response. Dosing is titrated to hemoglobin (Hb) values with the goal of using the lowest dose sufficient to reduce the need for RBC transfusions; specific dose limits and adjustment principles are described in the prescribing information and policy dosing sections.

Key Hemoglobin and Erythropoietin Thresholds

Hb initiation (adults, CKD on dialysis)< 10.0 g/dL

Hb reduce/interrupt (adults, on dialysis)approaches or exceeds 11.0 g/dL

Hb initiation (adults, CKD not on dialysis)< 10.0 g/dL

Pediatric Hb initiation (CKD, <18 y)< 10.0 g/dL (initiate); reduce/interrupt if approaches 12.0 g/dL

Hb threshold for continuing ESA-treated patients≤ 12.0 g/dL

Serum erythropoietin for MDS/myelofibrosis consideration≤ 500 mU/mL

Revision History

2024-10-15annual_revision

Annual Revision (10/15/2024): Updated title from 'Darbepoetin Alfa' to 'Erythropoiesis-Stimulating Agents - Aranesp'; added indications (CKD not on dialysis, cancer chemotherapy-related anemia, MDS, myelofibrosis) and dosing; added criteria 'Patient is Currently Receiving an Erythropoiesis-Stimulating Agent' for Anemia in an Individual with Cancer due to Cancer Chemotherapy; added language 'According to the prescriber, myelosuppressive chemotherapy is considered noncurative.'

2025-09-15annual_revisionLatest

Annual Revision (9/15/2025): Administrative update with note 'No criteria changes.' (effective date 9/15/2025; policy listing and dosing/indication structure retained from prior revision).

OpenPayer

Aranesp

Coverage Summary

Provider Actions & Billing

Applicable Codes

Clinical Evidence & References

Background

Revision History

J0881	Injection, darbepoetin alfa, 1 microgram (non-ESRD use)
J0882	Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)